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Botulinum toxin A (BTA) is a recognized treatment for the early management of spasticity in children with Cerebral Palsy. This
study quantiﬁed with Gait Analysis (GA) the gait pattern of a 4-year-old diplegic child with calf contracture before, 5 days, and
3 months after BTA injections into gastrocnemius. Kinematic and kinetic data of main lower limb joints were investigated. After
only 5 days, ankle dorsi-plantarﬂexion and knee ﬂex-extension improved, but hip joint worsened, increasing its excessive ﬂexion,
to compensate the improvement in knee position of the treated limb and to obtain better stability. A worsening of hip power
happened. After 3 months, all joints generally improved their position during gait cycle. Hip and knee joints increased their range
of movement and improvements occurred at ankle kinematics and kinetisc , too; a better ankle position and an increase of its
capacity of propulsion during terminal stance were evident.
Copyright © 2009 Veronica Cimolin et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The use of Botulinum toxin type A (BTA) has been
recommended in the management of spasticity in ambulant
children with Cerebral Palsy (CP) to improve function
and to delay the development of ﬁxed deformity and the
need for surgical intervention. Although its immediate
positive eﬀects have been quantiﬁed using Gait Analysis
(GA) in previous studies, especially for the treatment of calf
contracture [1–8], some limits emerged. First, in literature
the evaluation of gait changes after BTA injections for
reducing gastrocnemius contracture was focused only on
joints directly connected to gastrocnemius (knee and ankle
joints); concerning proximal joints (pelvis and hip joints)
no analyses were found. Then, all the studies quantifying
bothkinematicandkineticstrategieswereconductedonlyon
patients older than 6 years; few studies, in fact, investigated
gait pattern of younger children using GA, and in these
analyses only kinematics was evaluated, neglecting kinetic
data [2, 8]. It is important to underline that no study
evaluatedtheeﬀectsofthetreatmentfewdaysafterit,too;the
evaluations were generally conducted one or more months
after the treatment.
This study quantiﬁed with GA the eﬀects of BTA
injections into gastrocnemius for the reduction of excessive
knee ﬂexion due to calf spasticity in a 4-yr-old child with CP.
His gait was evaluated considering distal and proximal joints
and in term of kinematics, and kinetic data, too. He was
examined before, 5 days, and 3 months after BTA injections
intoleftgastrocnemius.Inthiswayacompletequantiﬁcation
of motor strategy of a very young patient was conducted.
2. Case Presentation
The patient was a 4-yr-old male (weight: 16Kg; height:
103cm) aﬀected by spastic diplegia; he was born approxi-
mately 7 weeks preterm with respiratory distress. He showed
a dynamic calf contracture and a stiﬀness of adductor
muscles; the left side was more worsened than the right one.
He was an independent community ambulator without the
use of assistive devices or orthoses.
The patient was injected 2 times, and in each inoculation
BTA (Botox, Allergan, USA) was injected intramuscularly in
thesamemusclesandwiththesamedosage:intheleftmedial
gastrocnemius (20U) and in the left lateral gastrocnemius2 Case Reports in Medicine
(15U). The temporal distance between the two inoculations
was 10 months. No side eﬀects or complications following
injections were found. He was examined before (PRE ses-
sion)and5days(POST1session)aftertheﬁrstBTAinjection
and 3 months (POST2) after the second BTA injection.
The patient was evaluated with 3D GA, using a 12-
camera optoelectronic system (ELITE2002, BTS S.p.A.,
Milan, Italy) with passive markers positioned according to
Davis [9], for kinematic movement [10], two force plat-
forms (Kistler, CH), for kinetic movement, and a synchronic
video system (BTS S.p.A., Milan, Italy). Seven trials were
collected for each session for the repeatability of the results.
Some parameters were identiﬁed and calculated from kine-
matic and kinetic data: spatiotemporal parameters, angles
joint values in speciﬁc gait cycle instant, and peak values
of joint powers. The mean values (standard deviation) of
kinematic and kinetic parameters are detailed, respectively,
in Tables 1 and 2, in PRE, POSTs sessions, and for normative
range (CG).
2.1. Pre Session. Child walked with a low velocity of pro-
gression (0.3+0 .1m/sec;CG:1.2+0 .2m/sec) and limited
anterior step length (right: 0.3+0 .1m and left: 0.3+0 .2m;
CG: 0.4+0 .1m), if compared to normative values. Pelvic
tilt was closed to normality. His gait was characterised by
excessive left hip ﬂexion at initial contact, while right side
was closed to normality; a reduced range of motion was
evident bilaterally, due to a limited extension in midstance.
Knee was characterised by abnormal ﬂexion during stance,
due to spasticity of gastrocnemius, showing a limited range
of motion bilaterally. Ankle joint was dorsiﬂexed during all
gait cycle, and the right side was the most compromised.
Right foot was in a correct position in the transversal plane,
while left foot was intrarotated during all gait cycle. Concern
kinetic data, a limited capacity of ankle propulsion during
terminal stance and a reduced peak of hip power generation
during stance phase were found bilaterally.
2.2. POST1 Session (5 Days After the First Injection). Velocity
of progression improved (0.7 ± 0.2m/sec), while the other
spatiotemporalparameterswereunchanged.Pelvictiltwasin
anterior position bilaterally and hip increased its ﬂexion on
rightside,whileleftoneimproveditsextensioninmidstance,
remaining above normality. Right knee joint did not change
signiﬁcantly, while the left side improved its position in
stance. The treatment reduced ankle dorsiﬂexion at right
side while left one remained generally unchanged. There
is a persistent drop foot in swing phase bilaterally, since
ankle joints were not able to achieve dorsiﬂexion. Both feet
weremoreintrarotatedthanPREsession.Concerningkinetic
data, a reduction of power generation at left ankle during
terminal stance occurred; hip power showed higher values of
positive peak in stance phase bilaterally.
2.3. POST2 Session (3 Months After the Second Injection). hip
joint reduced its excessive ﬂexion at initial contact on right
side, remaining above normality, and improved its extension
in mid-stance bilaterally, with consequently a better excur-
sion during movement. Knee showed a more physiological
position during stance phase with better range of motion.
Ankle reduced its excessive dorsiﬂexion bilaterally. The right
side was closed to normality during stance phase, and
the left side showed, in addiction, the worsening of ankle
dorsiﬂexion in swing phase. Foot progression improved
bilaterally. Concern kinetics, hip power improved at right
side, and maximum of ankle power increased bilaterally.
3. Discussion
In this study the kinematic and kinetic aspects of gait in a 4-
yr-old child with CP were evaluated using GA to quantify the
eﬀects of BTA injection into gastrocnemius for the reduction
of excessive knee ﬂexion due to calf spasticity. Literature
investigated widely this topic but it presents some limits:
only the eﬀects on ankle and knee pattern were evaluated
and those on proximal joints, as hip and pelvic joints, were
neglected. Then, patients were generally more than 6-yr-
old; few studies investigated gait strategy in younger children
using GA, but these analyses concerned only kinematics, not
kinetic data. In addition, the evaluations were conducted
generally one or more months after the treatment.
The results of this study demonstrated that the brief term
eﬀects of BTA occurred on all joints of lower limbs, not
only on joints directly connected to treated gastrocnemius,
knee, and ankle joints. Concerning pelvic joint, a worsening
happened in the sagittal plane, increasing the anterior tilt;
hip increased its ﬂexion and this condition was directly
connected to abnormal pelvic tilt position. The higher hip
ﬂexion at initial contact and the reduction of excessive knee
ﬂexion during stance phase on the treated side induced a
new biomechanical position: this condition may be directly
connectedtotheinitialreductionofgastrocnemiusspasticity
that allows the subject to experience greater extension of
left knee. At ankle joint some signiﬁcant improvements
occurred in the sagittal plane, while on coronal plane, the
treatment caused a worsening in foot progression bilaterally.
The excessive hip ﬂexion and foot intrarotation may be a
strategy to obtain a better stability and equilibrium. As knee
joint has a more physiological pattern on the treated side,
while the right side maintained its excessive ﬂexion, this
strategy probablyis a scheme that permits to walk the patient
with safety and at higher velocity of progression. In term
of kinetics, before the treatment, the spastic gastrocnemius
induced a reduction of ankle power generation at terminal
stance, because this muscle is not able to strongly contract in
this phase; after injection no changes occurred. This result
was connected to the nature of BTA that denervates and
produces a temporary paralysis of the treated muscle. The
worsening of positive hip power in stance may be related to
thehighhipﬂexionatinitialcontactandtothereducedankle
power generation at terminal stance, too: the low levels of
ankle work resulted in greater amounts of work being done
by muscle groups of the hip.
Three months after the second injection of BTA, gait
pattern revealed a general improvement, both at proximal
and distal joints. Hip reduced its abnormal ﬂexion at initial
contact on right side and revealed an improvement in hip
extension in mid-stance bilaterally. A better position andCase Reports in Medicine 3
Table 1: Summary of kinematic parameters (mean and standard deviation) for analysed patient (CP patient; right and left side) in the
examined sessions and normative data (Control Group, CG). ROM: Range Of Motion; Min: Minimum value; Max: Maximum value; IC:
Initial Contact; St: Stance phase; Sw: Swing phase.
CP patient PRE CP patient POST1 (5 days) CP patient POST2 (3 months) CG
right left right left right left
Pelvic Tilt (degrees)
Mean Pelvic Tilt 6.6( 1 .3) 6.8( 0 .4) 16.2( 1 .7) 16.4( 2 .1) 15.7( 0 .8) 16.0( 0 .1) 8.8( 4 .3)
ROM 5.9( 1 .5) 5.4( 0 .3) 7.5( 2 .1) 6.5( 1 .1) 5.7( 0 .5) 5.0( 1 .5) 1.6( 3 .6)
Hip Flex-Extension (degrees)
IC 30.4( 0 .1) 38.4( 1 .4) 45.5( 0 .7) 34.4( 0 .9) 40.5( 0 .5) 33.2( 1 .5) 29.5( 4 .4)
M i ni nS t 6 .4( 0 .9) 21.5( 2 .1) 13.8( 1 .1) 16.0( 1 .2) −0.8( 2 .5) 10.9( 0 .3) −8.7( 6 .4)
Knee Flex-Extension (degrees)
IC 29.3( 1 .8) 35.7( 1 .1) 25.8( 2 .2) 22.3( 3 .7) 16.4( 2 .3) 13.6( 2 .3) 6.7( 5 .5)
M i ni nm i s S t 2 3 .4( 3 .8) 25.7( 1 .0) 22.1( 0 .4) 13.2( 3 .9) 0.4( 2 .7) 2.0( 0 .9) 4.2( 2 .1)
ROM 29.8( 3 .9) 22.4( 1 .2) 33.7( 0 .8) 27.7( 2 .6) 61.1( 2 .7) 47.5( 1 .7) 58.8( 4 .7)
Ankle Dorsi-Plantarﬂexion (degrees)
IC 14.4( 2 .5) 9.3( 0 .6) 9.4( 1 .5) 10.4( 2 .3) −3.9( 1 .3) −3.0( 0 .9) −0.5( 4 .8)
Max in St 29.4( 1 .6) 18.7( 3 .1) 19.7( 3 .1) 24.4( 2 .7) 14.7( 1 .8) 8.7( 0 .9) 12.2( 5 .5)
ROM in Sw 8.3( 2 .2) 4.3( 3 .3) 4.6( 7 .1) 8.1( 1 .7) 5.4( 0 .9) 4.2( 2 .5) 23.3( 5 .5)
Foot Progression (degrees)
Mean foot progression −13.2( 3 .3) 7.3( 1 .5) 3.2( 1 .6) 21.4( 0 .3) −12.2( 0 .2) −3.4( 2 .8) −12.7( 4 .4)
Table 2:Summaryofkineticparameters(meanandstandarddeviation)foranalysedpatient(CPpatient;rightandleftside)intheexamined
sessions and normative data (Control Group, CG). Max: Maximum value; St: Stance phase.
CP patient PRE CP patient POST1 (5 days) CP patient POST2 (3 months) CG
right left right left right left
Hip Power (W/Kg)
Max of generation in St 0.2 (0.1) 0.3 (0.2) 0.8 (0.2) 0.5 (0.2) 0.5 (0.3) 0.4 (0.4) 0.8 (0.4)
Ankle Power (W/Kg)
Max of generation during terminal St 0.7 (0.5) 1.0 (0.9) 0.6 (0.2) 0.4 (0.3) 2.7 (0.1) 2.6 (0.7) 3.3 (1.1)
a good excursion of knee during all gait cycle bilaterally
were evident. In this way a reduction of knee asymmetry,
present in POST1 session, disappeared, allowing the subject
to show more physiological knee ﬂexion during most of
gait cycle: a knee ﬂexion reduction and a better extension
would facilitate a corresponding increase of hip extension,
to maintain erect posture during gait. Ankle improved its
position during all stance phase; in swing phase instead
the range of motion remained low. Even if the treatment
reduced the dominance of the ankle plantarﬂexors over the
antagonist muscles and so tibialis anterior is not contrasted
by the abnormal gastrocnemius activity any more, probably
the dorsiﬂexor muscle is again weak avoiding the correct
position of ankle joint during swing. Concern kinetic results,
a better capacity of propulsion at ankle joint is evident :
the improvement may be due to the conclusion of temporary
paralysis of treated muscle that now can contract during
terminal stance. Hip power reduced on the right side its
maximum in stance phase, according to decrease of hip
ﬂexion.
From these results, it is evident that BTA represents
an encouraging therapy for the reduction of spasticity in
CP subjects. In particular this study demonstrated that the
treatment performed on a very young patient has signiﬁcant
eﬀects immediately few days after the treatment. These
modiﬁcations, that were worsening at proximal joints and
improvements at distal ones, may be due to the search
of a new control strategy immediately required after the
reduction of gastrocnemius spasticity: the modiﬁcations at
distal joints, directly connected to treatment of gastroc-
nemius, probably induce postural adjustments at proximal
joints. Some months after the second inoculation, gait
pattern revealed a general improvement, both at proximal
and distal joints, demonstrating the reaching of better
stability and reorganization of motor scheme of the patient.
These signiﬁcant changes may be directly connected to
the eﬀects of the BTA inoculation into the spastic mus-
cles and to the natural maturation of the gait in the
patient, too: the reduction of the spasticity during the
growth period may reduce muscle tone and allow normal
longitudinal muscle growth and lengthening leading to a
more physiological gait pattern. Future studies might be
conducted to compare children with the same age treated
a n dn o tt r e a t e dw i t hB T A ,i no r d e rt oe x c l u d eo n ee ﬀect
(the natural maturation of gait) with respect to the other
(eﬀects of BTA).4 Case Reports in Medicine
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